Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States

A Benedict; RA Figlin; C Charbonneau; N Kreif; S Hariharan; S Négrier

Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States

A Benedict, RA Figlin, C Charbonneau, N Kreif, S Hariharan, S Négrier

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	e17556-e17556
Journal	Journal of Clinical Oncology
Volume	27
Issue number	15S
Publication status	Published - 2009

Cite this

@article{35f3e6af466546509253f9a98b1d0cf4,

title = "Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States",

author = "A Benedict and RA Figlin and C Charbonneau and N Kreif and S Hariharan and S N{\'e}grier",

year = "2009",

language = "English",

volume = "27",

pages = "e17556--e17556",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15S",

}

TY - JOUR

T1 - Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States

AU - Benedict, A

AU - Figlin, RA

AU - Charbonneau, C

AU - Kreif, N

AU - Hariharan, S

AU - Négrier, S

PY - 2009

Y1 - 2009

M3 - Article

SN - 0732-183X

VL - 27

SP - e17556-e17556

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15S

ER -